{"id":"W2955874948","doi":"10.1016/s1474-4422(19)30137-1","title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Acorda Therapeutics; Celgene; Biogen","keywords":"Placebo; Multiple sclerosis; Medicine; Phase (matter); Internal medicine; Physical therapy; Alternative medicine; Psychiatry; Chemistry; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001960306,0.002141082,0.003799215,0.0004759861,0.0005790676,0.001126063,0.0008148088,0.002546513,0.005129473],"category_scores_gemma":[0.002261319,0.0008119607,0.003212159,0.0003762304,0.001256146,0.001256306,0.0005976842,0.003321967,0.0008681485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007248803,"about_ca_system_score_gemma":0.001007577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000785843,"about_ca_topic_score_gemma":0.001744469,"domain_scores_codex":[0.9991763,0.0004122932,0.00006468908,0.000146017,0.00006683241,0.0001338175],"domain_scores_gemma":[0.9986507,0.0004223871,0.0003676573,0.00009747058,0.00009305899,0.0003686843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9846461,0.002123219,0.000713333,0.0008616213,0.001376266,0.00004152864,0.00004791282,0.0001298041,0.001731952,0.00004821203,0.0003694212,0.007910611],"study_design_scores_gemma":[0.9528021,0.04356438,0.002186865,0.00004680148,0.0007200901,0.00004094286,0.00002161409,0.0001250494,0.0001676651,0.00006446581,0.000246013,0.00001392291],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867137,0.008111265,0.0003493589,0.0006923266,0.0004349513,0.001649141,0.0006454286,0.0000634178,0.001340399],"genre_scores_gemma":[0.9906055,0.003298018,0.0007939843,0.001043922,0.0004969492,0.001470691,0.000727877,0.00001579652,0.001547273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005129473,"threshold_uncertainty_score":0.01715982,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03542653499353299,"score_gpt":0.2888135071652921,"score_spread":0.2533869721717591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}